Hemophagocytic Lymphohistiocytosis (HLH)

Hemophagocytic lymphohistiocytosis (HLH) is a rare but life‑threatening syndrome of uncontrolled immune activation. In HLH, certain white blood cells—particularly macrophages and lymphocytes—become over‑stimulated, engulf healthy blood cells, and release massive amounts of cytokines. This “cytokine storm” leads to persistent high fever, enlarged liver and spleen, low blood cell counts, and organ failure if untreated ASH Publications. HLH is classified as primary (familial)—due to inherited genetic mutations affecting immune regulation—or secondary (acquired)—triggered by infections (especially EBV), malignancies, or autoimmune diseases ASH Publications. Early recognition and treatment are vital: without prompt intervention, mortality exceeds 50%.

Hemophagocytic lymphohistiocytosis (HLH) is a severe, life-threatening syndrome in which the body’s immune system becomes overactive, leading to widespread inflammation and tissue damage. In HLH, specialized immune cells—particularly natural killer (NK) cells, cytotoxic T-cells, and macrophages—fail to regulate their response, releasing excessive inflammatory signals called cytokines. This “cytokine storm” causes fever, organ enlargement, and progressive organ failure if not promptly treated NCBI.

At its core, HLH represents a breakdown in the normal checks and balances of the immune system. Under healthy conditions, NK cells and cytotoxic T-cells identify and destroy infected or abnormal cells by releasing enzymes like perforin and granzyme. In HLH, genetic defects or external triggers impair this process, causing immune cells to proliferate uncontrollably and attack healthy tissues throughout the body NCBI.

Types of HLH

1. Primary (Familial) HLH arises from inherited genetic mutations that disrupt the ability of NK cells and cytotoxic T-cells to kill target cells. These mutations are often autosomal recessive and may be associated with syndromes such as Chediak–Higashi or Griscelli. Children with primary HLH typically present before one year of age, often with severe, rapidly progressing symptoms driven by unchecked inflammation NCBI.
2. Secondary (Acquired) HLH occurs when an external trigger—such as infection, malignancy, autoimmune disease, certain medications, or organ transplantation—provokes an overwhelming immune response in someone without the classic familial mutations. Although it can affect individuals of any age, secondary HLH is most often diagnosed in adults and may develop in the course of severe infections or cancer treatment NCBI.

Main Causes

1. PRF1 (Perforin) Mutation
   Perforin is a protein used by NK cells and cytotoxic T-cells to punch holes in target cell membranes. Mutations in the PRF1 gene prevent effective cytotoxic killing, leading to persistent immune activation and the development of primary HLH Wikipedia.

2. UNC13D (Munc13-4) Mutation
   The UNC13D gene encodes a protein critical for priming cytotoxic granules before they are released. Defective Munc13-4 results in the inability of immune cells to secrete perforin effectively, fueling the hyperinflammatory state in familial HLH Wikipedia.

3. STX11 (Syntaxin 11) Mutation
   Syntaxin 11 is involved in the fusion of cytotoxic granules with the immune cell membrane. Mutations in STX11 disrupt this fusion process, causing accumulation of activated immune cells and excessive cytokine release characteristic of HLH Wikipedia.

4. STXBP2 (Munc18-2) Mutation
   Munc18-2 regulates syntaxin-mediated granule fusion. Loss-of-function mutations in STXBP2 lead to impaired granule exocytosis in immune cells, driving uncontrolled macrophage activation and hemophagocytosis Wikipedia.

5. RAB27A Mutation
   RAB27A controls granule docking at the cell membrane. Mutations here not only cause familial HLH but also underlie Griscelli syndrome type 2, linking pigmentary defects with immune dysregulation and hemophagocytosis Wikipedia.

6. LYST Mutation
   The LYST gene is mutated in Chediak–Higashi syndrome, which features giant lysosomal granules in multiple cell types. Patients with LYST mutations can develop HLH due to defective lysosome trafficking and consequent immune hyperactivation Wikipedia.

7. SH2D1A Mutation
   SH2D1A encodes SAP, an adaptor protein in T and NK cells. X-linked lymphoproliferative disease type 1 arises from SH2D1A mutations, predisposing to life-threatening EBV-triggered HLH Wikipedia.

8. BIRC4 (XIAP) Mutation
   XIAP deficiency, caused by BIRC4 mutations, impairs apoptosis regulation and predisposes to recurrent, severe HLH episodes, often associated with EBV infection Wikipedia.

9. ITK Mutation
   Interleukin-2–inducible T-cell kinase (ITK) is necessary for T-cell receptor signaling. Rare ITK mutations can present as familial HLH with dysregulated T-cell activation and cytokine release Wikipedia.

10. CD27 Mutation
    CD27 supports survival of activated lymphocytes. Mutations in CD27 disrupt T-cell and NK-cell homeostasis, leading to immune overactivation and HLH Wikipedia.

11. MAGT1 Mutation
    Magnesium transporter 1 (MAGT1) deficiency affects T-cell signaling and can manifest as X-linked immunodeficiency with episodes of HLH Wikipedia.

12. Epstein–Barr Virus (EBV) Infection
    EBV infects B cells and can trigger an overwhelming immune response. Approximately half of infection-associated HLH cases are due to EBV reactivation or primary infection Wikipedia.

13. Cytomegalovirus (CMV) Infection
    CMV can induce HLH in both immunocompetent and immunocompromised individuals by driving persistent macrophage and T-cell activation Wikipedia.

14. HIV/AIDS
    Advanced HIV infection and the associated immune dysregulation can precipitate HLH during opportunistic infections or as part of HIV-related immune activation Wikipedia.

15. Bacterial Sepsis
    Severe bacterial infections, particularly gram-negative sepsis, may lead to secondary HLH by triggering massive cytokine release from activated macrophages Wikipedia.

16. Fungal Infections
    Invasive fungal diseases (e.g., histoplasmosis) can act as HLH triggers, with disseminated infection stimulating uncontrolled macrophage proliferation Wikipedia.

17. T-Cell Lymphoma
    Malignancies of the T-cell lineage often present with HLH because the malignant cells themselves can produce large amounts of cytokines Wikipedia.

18. B-Cell Lymphoma
    B-cell lymphomas, particularly diffuse large B-cell lymphoma, may provoke HLH by disrupting normal immune regulation and creating proinflammatory microenvironments Wikipedia.

19. Systemic Lupus Erythematosus (SLE)
    Active SLE flares involve profound cytokine release and immune complex formation, which can overlap with HLH features known as macrophage activation syndrome Wikipedia.

20. Adult-Onset Still’s Disease (AOSD)
    AOSD is a systemic inflammatory disorder characterized by high fevers, rash, and arthritis; its cytokine-driven inflammation can evolve into HLH in a subset of patients Wikipedia.

Key Symptoms

1. Fever
   Patients with HLH almost always have prolonged, unremitting fever driven by high levels of interleukin-1 and tumor necrosis factor Wikipedia.

2. Splenomegaly
   Enlargement of the spleen occurs in most cases, reflecting activated macrophages filtering blood cells and tissue debris Wikipedia.

3. Hepatomegaly
   The liver often swells as activated histiocytes infiltrate hepatic tissue, contributing to abdominal discomfort and elevated liver enzymes Wikipedia.

4. Lymphadenopathy
   Inflamed lymph nodes throughout the body arise from excessive proliferation of immune cells Wikipedia.

5. Jaundice
   Yellow discoloration of the skin and eyes can result from liver dysfunction and hemophagocytic destruction of red blood cells Wikipedia.

6. Rash
   A maculopapular or petechial rash may appear due to cytokine-mediated vascular leakage and low platelet counts Wikipedia.

7. Anemia
   Destruction of red blood cells by activated macrophages and bone marrow suppression leads to fatigue and pallor Wikipedia.

8. Thrombocytopenia
   Low platelet counts contribute to bleeding tendencies, from easy bruising to serious hemorrhage Wikipedia.

9. Neutropenia
   Reduced neutrophil levels predispose to secondary bacterial and fungal infections Wikipedia.

10. Hyperferritinemia
    Ferritin—an acute-phase reactant—rises dramatically in HLH, often exceeding thousands of micrograms per liter Wikipedia.

11. Hypertriglyceridemia
    Impaired lipoprotein lipase activity and cytokine effects drive elevated blood triglyceride levels Wikipedia.

12. Hypofibrinogenemia
    Consumption of clotting factors by activated macrophages and fibrinolysis leads to low fibrinogen levels and bleeding risk Wikipedia.

13. Elevated Liver Enzymes (Transaminitis)
    AST and ALT rise as hepatocytes are injured by infiltrating immune cells Wikipedia.

14. Elevated Lactate Dehydrogenase (LDH)
    Cell turnover and tissue damage elevate LDH, marking widespread cell injury Wikipedia.

15. Neurologic Symptoms
    Seizures, irritability, and ataxia may occur when HLH involves the central nervous system Wikipedia.

Diagnostic Tests

Physical Examination Tests

1. Temperature Measurement
   Continuous monitoring of body temperature confirms persistent fever, a hallmark of HLH NCBI.

2. Splenomegaly Palpation
   Gentle abdominal palpation can detect an enlarged spleen, suggesting reticuloendothelial activation NCBI.

3. Hepatomegaly Palpation
   Liver enlargement is assessed by measuring the liver edge below the right costal margin NCBI.

4. Lymph Node Examination
   Enlarged, tender lymph nodes may be detected in cervical, axillary, or inguinal regions NCBI.

Manual (Procedural) Tests

5. Bone Marrow Aspiration
   A sample of marrow is drawn to look for hemophagocytosis under the microscope NCBI.

6. Bone Marrow Biopsy
   A core of marrow tissue provides histopathologic confirmation of macrophage infiltration NCBI.

7. Peripheral Blood Smear
   Manual review of blood cells can show hemophagocytic macrophages and other abnormalities NCBI.

8. NK-Cell Cytotoxicity Assay
   Functional testing of NK-cell activity helps meet HLH-2004 diagnostic criteria NCBI.

Laboratory and Pathological Tests

9. Complete Blood Count (CBC)
   Identifies cytopenias affecting red cells, white cells, and platelets NCBI.

10. Serum Ferritin
    Extremely high ferritin levels support the diagnosis of HLH NCBI.

11. Serum Triglycerides
    Elevated triglycerides are part of HLH-2004 criteria NCBI.

12. Fibrinogen Level
    Low fibrinogen reflects consumptive coagulopathy NCBI.

13. Soluble IL-2 Receptor (sCD25)
    High levels indicate T-cell activation and are included in diagnostic criteria NCBI.

14. Liver Function Tests
    AST, ALT, bilirubin, and albumin measurements assess hepatic involvement NCBI.

15. Coagulation Tests (PT, aPTT)
    Prolonged clotting times may indicate ongoing inflammation and liver dysfunction NCBI.

Electrodiagnostic Tests

16. Electroencephalography (EEG)
    In patients with neurologic symptoms such as seizures or altered consciousness, EEG may reveal diffuse slowing and epileptiform activity PMC.

17. Electromyography (EMG)
    EMG can assess neuromuscular involvement when patients present with weakness or peripheral nerve symptoms NCBI.

Imaging Tests

18. Chest X-Ray
    May show lung infiltrates or pleural effusions related to pulmonary inflammation PMC.

19. Abdominal Ultrasound
    Non-invasive detection of hepatosplenomegaly and lymphadenopathy; useful for guiding biopsies American Journal of Roentgenology.

20. Computed Tomography (CT) Scan
    Offers detailed images of organ enlargement, lymph node clusters, and potential focal lesions American Journal of Roentgenology.

---

Non‑Pharmacological Treatments

Below are twenty supportive and procedural therapies used alongside drugs to control inflammation, support organ function, and improve outcomes in HLH.

1. Therapeutic Plasma Exchange (TPE)
   Description & Purpose: TPE removes circulating cytokines and immune complexes from the blood.
   Mechanism: Blood is passed through a filter that separates plasma (removed) from cells; patient’s plasma is replaced with albumin or donor plasma, reducing cytokine load and immune activation PubMed.

2. Extracorporeal Photopheresis (ECP)
   Description & Purpose: ECP treats hyperinflammation by treating a patient’s white cells with a photosensitizing agent and UV light, then reinfusing them.
   Mechanism: UV‑treated cells induce regulatory T‑cell expansion and shift cytokine balance toward anti‑inflammatory profiles PubMed.

3. Renal Replacement Therapy (RRT)
   Description & Purpose: Continuous dialysis supports kidney function when HLH‑related shock causes acute kidney injury.
   Mechanism: Removes waste and excess fluid, stabilizing electrolyte and acid‑base balance.

4. Mechanical Ventilation
   Description & Purpose: Provides respiratory support in HLH patients with lung injury or ARDS.
   Mechanism: Maintains oxygenation and ventilation while underlying inflammation is treated.

5. Nutritional Support & Dietetic Counseling
   Description & Purpose: Ensures adequate calories, protein, and micronutrients during hypercatabolic state.
   Mechanism: Tailored enteral or parenteral nutrition prevents malnutrition and supports immune function.

6. Physical Therapy
   Description & Purpose: Prevents deconditioning in critically ill HLH patients.
   Mechanism: Guided exercises maintain muscle mass and improve functional recovery.

7. Occupational Therapy
   Description & Purpose: Helps patients adapt to daily activities impaired by weakness or neurological involvement.
   Mechanism: Teaches energy‑conservation techniques and use of assistive devices.

8. Psychological Counseling & Support Groups
   Description & Purpose: Addresses anxiety, depression, and stress associated with severe illness.
   Mechanism: Cognitive‑behavioral strategies and peer support improve coping and quality of life.

9. Strict Infection Control Measures
   Description & Purpose: Prevents opportunistic infections in immunocompromised HLH patients.
   Mechanism: Hand hygiene, protective isolation, and antimicrobial stewardship reduce infection risk.

10. Fever Management & Cooling Therapy
    Description & Purpose: Controls high fevers that exacerbate metabolic demand.
    Mechanism: Antipyretics and physical cooling (cooling blankets) reduce cytokine‑driven hyperthermia.

11. Blood Product Support
    Description & Purpose: Transfusions of red cells and platelets correct cytopenias.
    Mechanism: Maintains oxygen delivery and prevents bleeding complications.

12. Iron Chelation (when indicated)
    Description & Purpose: Removes excess iron in patients receiving multiple transfusions.
    Mechanism: Chelating agents bind free iron, reducing oxidative damage.

13. Vitamin & Micronutrient Support
    Description & Purpose: Corrects deficiencies that impair immunity (e.g., vitamins C, D, zinc).
    Mechanism: Supports barrier function and antioxidant defenses.

14. Palliative Care Integration
    Description & Purpose: Manages symptoms, supports families, and facilitates goals‑of‑care discussions.
    Mechanism: Multidisciplinary approach ensures comfort and psychosocial support.

15. Multi‑Disciplinary Case Conferences
    Description & Purpose: Coordinates care among hematology, ICU, infectious disease, and other teams.
    Mechanism: Regular planning meetings optimize timing of therapies and procedures.

16. Genetic Counseling (for familial HLH)
    Description & Purpose: Informs families about inheritance patterns and risks to siblings.
    Mechanism: Offers carrier testing and prenatal options when applicable.

17. Education on Early Symptom Recognition
    Description & Purpose: Empowers caregivers to seek care promptly at fever onset.
    Mechanism: Reduces diagnostic delay and organ damage.

18. Home Health Nursing
    Description & Purpose: Provides wound care, medication administration, and vital‑sign monitoring post‑discharge.
    Mechanism: Supports safe transition out of hospital and early detection of relapse.

19. Social Work & Financial Counseling
    Description & Purpose: Helps families navigate care expenses and resources.
    Mechanism: Reduces stress and ensures treatment adherence.

20. Mind‑Body Interventions (e.g., meditation, guided imagery)
    Description & Purpose: Alleviates stress and may modulate inflammation.
    Mechanism: Activates parasympathetic pathways and lowers stress hormone release.

---

Key Drugs for HLH

These medications form the backbone of HLH therapy. Dosages are typically weight‑based and adjusted for age and organ function.

1. Etoposide (VP‑16)

   • Class: Topoisomerase II inhibitor

   • Dosage: 150 mg/m² IV twice weekly for first 2 weeks, then weekly PubMed

   • Schedule: As per HLH‑94/2004 protocol

   • Side Effects: Myelosuppression, mucositis, alopecia, risk of secondary leukemia.

2. Dexamethasone

   • Class: Corticosteroid

   • Dosage: 10 mg/m²/day IV days 1–2, taper over 8 weeks PubMed

   • Purpose: Suppresses cytokine production.

   • Side Effects: Hyperglycemia, hypertension, mood changes, osteoporosis.

3. Cyclosporine A

   • Class: Calcineurin inhibitor

   • Dosage: 6 mg/kg/day PO in two doses, target trough 200–300 ng/mL PubMed

   • Purpose: Inhibits T‑cell activation.

   • Side Effects: Nephrotoxicity, hypertension, neurotoxicity.

4. Intrathecal Methotrexate

   • Class: Antimetabolite

   • Dosage: 12 mg via Ommaya reservoir or lumbar puncture on days 1, 8, and 15 for CNS HLH PubMed

   • Purpose: Treats or prevents central nervous system involvement.

   • Side Effects: Neurotoxicity, headaches, chemical arachnoiditis.

5. Emapalumab

   • Class: Anti‑IFN‑γ monoclonal antibody

   • Dosage: 1 mg/kg IV twice weekly; may escalate to 10 mg/kg BioMed Central

   • Purpose: Neutralizes interferon‑γ, a key cytokine in HLH.

   • Side Effects: Infection risk, infusion reactions.

6. Anakinra

   • Class: IL‑1 receptor antagonist

   • Dosage: 2–10 mg/kg/day subcutaneously BioMed Central

   • Purpose: Blocks IL‑1–driven inflammation.

   • Side Effects: Injection‑site reactions, neutropenia.

7. Ruxolitinib

   • Class: JAK1/2 inhibitor

   • Dosage: 5–10 mg twice daily (adult) BioMed Central

   • Purpose: Inhibits JAK‑STAT–mediated cytokine signaling.

   • Side Effects: Cytopenias, elevated liver enzymes, infection.

8. Tocilizumab

   • Class: Anti‑IL‑6 receptor monoclonal antibody

   • Dosage: 8 mg/kg IV once; may repeat every 2 weeks BioMed Central

   • Purpose: Reduces IL‑6–mediated effects, part of cytokine storm.

   • Side Effects: Hepatotoxicity, dyslipidemia, GI perforation.

9. Alemtuzumab

   • Class: Anti‑CD52 monoclonal antibody

   • Dosage: 0.01–0.03 mg/kg/day IV for 3 days BioMed Central

   • Purpose: Depletes activated lymphocytes and macrophages.

   • Side Effects: Profound immunosuppression, infusion reactions.

10. Intravenous Immunoglobulin (IVIG)

    • Class: Immunomodulator

    • Dosage: 1–2 g/kg over 1–2 days PubMed

    • Purpose: Modulates Fc‑receptor–mediated activation of macrophages.

    • Side Effects: Headache, thrombosis, renal dysfunction.

---

Dietary Molecular Supplements

These supplements may support immune balance and reduce oxidative stress in HLH. Note: Always discuss with your care team before starting any supplement.

1. Vitamin D₃

   • Dosage: 2,000 IU daily

   • Function: Modulates innate and adaptive immunity.

   • Mechanism: Binds vitamin D receptor on macrophages/T cells, downregulating pro‑inflammatory cytokines.

2. Zinc

   • Dosage: 20–40 mg elemental zinc daily

   • Function: Supports lymphocyte function and barrier integrity.

   • Mechanism: Cofactor for thymulin, attenuates NF‑κB activation.

3. Selenium

   • Dosage: 100–200 µg daily

   • Function: Antioxidant and immune modulator.

   • Mechanism: Component of glutathione peroxidase, reduces oxidative damage.

4. Omega‑3 Fatty Acids (Fish Oil)

   • Dosage: 1–3 g EPA/DHA daily

   • Function: Anti‑inflammatory effects.

   • Mechanism: EPA/DHA-derived resolvins limit neutrophil infiltration.

5. Curcumin

   • Dosage: 500–1,000 mg standardized extract twice daily

   • Function: Broad anti‑inflammatory agent.

   • Mechanism: Inhibits NF‑κB and COX‑2 pathways.

6. Resveratrol

   • Dosage: 200–500 mg daily

   • Function: Antioxidant and SIRT1 activator.

   • Mechanism: Downregulates pro‑inflammatory cytokine production.

7. Quercetin

   • Dosage: 500 mg twice daily

   • Function: Mast cell stabilizer, antioxidant.

   • Mechanism: Inhibits histamine release and cytokine secretion.

8. N‑Acetylcysteine (NAC)

   • Dosage: 600 mg two times daily

   • Function: Glutathione precursor, antioxidant.

   • Mechanism: Replenishes intracellular GSH, scavenges free radicals.

9. Probiotic Blend (Lactobacillus & Bifidobacterium)

   • Dosage: ≥10 billion CFU daily

   • Function: Supports gut barrier and immune homeostasis.

   • Mechanism: Modulates T‑cell responses and endotoxin translocation.

10. L‑Glutamine

    • Dosage: 0.3–0.5 g/kg/day

    • Function: Fuel for rapidly dividing immune cells and enterocytes.

    • Mechanism: Supports lymphocyte proliferation and gut health.

---

Regenerative & Stem‑Cell–Based Therapies

These emerging therapies aim to restore normal immune regulation or replace defective immune systems.

1. Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

   • Dosage: Conditioning + 10⁶–10⁷ CD34⁺ cells/kg

   • Function: Replaces defective immune system in familial HLH.

   • Mechanism: Donor stem cells engraft, generate healthy macrophages and lymphocytes ASH Publications.

2. Mesenchymal Stem Cell (MSC) Infusion

   • Dosage: 1–2 × 10⁶ cells/kg IV every 2–4 weeks (experimental)

   • Function: Immunomodulatory support.

   • Mechanism: MSCs secrete anti‑inflammatory cytokines (IL‑10, TGF‑β).

3. Emapalumab (as above)

   • Function: Biological replacement therapy targeting IFN‑γ.

   • Mechanism: Binds and neutralizes IFN‑γ, reducing inflammation.

4. Ruxolitinib (as above)

   • Function: Small‑molecule regenerative in cytokine storm.

   • Mechanism: JAK‑STAT pathway blockade restores immune balance.

5. Gene Therapy (Investigational)

   • Dosage: Single infusion of viral vector–corrected HSCs

   • Function: Corrects genetic defect in primary HLH.

   • Mechanism: Ex vivo gene correction of PRF1, UNC13D, or other HLH genes.

6. Oprelvekin (IL‑11)

   • Dosage: 25 µg/kg/day subcutaneously (off‑label)

   • Function: Stimulates platelet and megakaryocyte recovery.

   • Mechanism: Binds IL‑11 receptor, promotes megakaryopoiesis and supports hematopoiesis.

---

Surgical Procedures & Why They’re Done

Though HLH is primarily medical, several procedures aid diagnosis or therapy delivery.

1. Bone Marrow Biopsy

   • Why: Confirms hemophagocytosis and rules out malignancy.

2. Splenectomy

   • Why: Rarely, to relieve massive splenomegaly causing pain or cytopenias.

3. Liver Biopsy

   • Why: Assesses hepatic infiltration if liver failure is unexplained.

4. Lymph Node Excisional Biopsy

   • Why: Identifies underlying lymphoma or other triggers.

5. Central Venous Catheter Placement

   • Why: Secure access for frequent infusions (chemo, IVIG).

6. Ommaya Reservoir Insertion

   • Why: Delivers intrathecal therapy for CNS HLH involvement.

7. Hematopoietic Stem Cell Harvest

   • Why: Collects donor cells before HSCT.

8. Skin Biopsy

   • Why: Investigates rash or macrophage infiltration in cutaneous HLH.

9. Splenic Artery Embolization

   • Why: Non‑surgical alternative to reduce spleen size and bleeding risk.

10. Percutaneous Liver Drainage

    • Why: Manages HLH‑related cholestasis or hepatic abscess.

---

Prevention Strategies

1. Early Genetic Screening in families with HLH history.

2. Prompt Treatment of EBV & Other Infections to avert secondary HLH.

3. Vaccinations (inactivated only) before immunosuppression.

4. Avoid Live Vaccines when receiving biologics (e.g., emapalumab).

5. Regular Monitoring of Ferritin & CBC in high‑risk patients.

6. Strict Asepsis in neutropenic phases.

7. Transfusion Safety to minimize alloimmunization.

8. Avoidance of Excessive Cytokine‑Releasing Triggers (e.g., certain biologics).

9. Family Education about HLH warning signs.

10. Multidisciplinary Follow‑Up post‑therapy to detect relapse early.

---

When to See a Doctor

Seek urgent medical attention if you experience:

• Fever >38.5 °C for more than 3 days

• Unexplained bruising or bleeding

• Rapid enlargement of spleen or liver (feel fullness under ribs)

• Persistent fatigue or weakness

• New neurological symptoms (seizures, confusion)

• Shortness of breath or chest pain

• Sudden drops in blood counts on routine labs

• Signs of organ failure (jaundice, decreased urine output)

• Severe infection in context of prior HLH

• Relapse signs after transplant or remission

---

Foods to Eat & 10 to Avoid

Eat (+):

1. Lean Proteins: Chicken, turkey, fish.

2. Leafy Greens: Spinach, kale rich in antioxidants.

3. Berries: Blueberries, strawberries for vitamin C.

4. Whole Grains: Brown rice, quinoa for energy.

5. Legumes: Lentils, beans for protein and fiber.

6. Nuts & Seeds: Almonds, chia for healthy fats.

7. Fermented Foods: Yogurt, kefir for gut health.

8. Colorful Vegetables: Bell peppers, carrots for micronutrients.

9. Bone Broth: Protein and minerals easy on digestion.

10. Hydrating Fluids: Water, herbal teas to support metabolism.

Avoid (–):

1. Alcohol: Increases liver stress.

2. Processed Meats: High in preservatives.

3. Sugary Drinks & Snacks: Fuel inflammation.

4. Trans Fats & Fried Foods: Worsen cytokine production.

5. Unpasteurized Dairy: Infection risk.

6. Raw Seafood & Eggs: Risk of pathogens.

7. Excess Red Meat: Can overload iron stores.

8. High‑Salt Processed Foods: Raise blood pressure.

9. Artificial Sweeteners: May disrupt gut microbiome.

10. Energy Drinks/Caffeine Excess: May stress heart and immune function.

---

Frequently Asked Questions

1. What is HLH?
   HLH is a hyperinflammatory syndrome in which immune cells overactivate and damage organs.

2. What causes HLH?
   It can be genetic (familial HLH) or triggered by infections, cancers, or autoimmune diseases.

3. How is HLH diagnosed?
   Diagnosis uses HLH‑2004 criteria: fever, cytopenias, high ferritin, hemophagocytosis on biopsy, NK‑cell activity, soluble IL‑2 receptor levels PubMed.

4. Can HLH be cured?
   Primary HLH often requires stem cell transplant for cure; secondary HLH may resolve with trigger treatment and immunotherapy.

5. What is the first‐line treatment?
   Etoposide plus dexamethasone with or without cyclosporine under HLH‑94/2004 protocols.

6. What are the risks of treatment?
   Treatments can cause infections, organ toxicity, and long‑term side effects like infertility.

7. Is HLH hereditary?
   Familial HLH follows autosomal recessive inheritance; genetic counseling is advised.

8. Can adults get HLH?
   Yes—secondary HLH is more common in adolescents and adults.

9. What is a cytokine storm?
   An extreme immune response releasing large quantities of cytokines, leading to tissue damage.

10. Are there targeted therapies?
    Yes—emapalumab (anti‑IFN‑γ), ruxolitinib (JAK inhibitor), anakinra (IL‑1 blocker).

11. When is stem cell transplant needed?
    In familial HLH or refractory secondary HLH to replace defective immune cells.

12. Can diet help manage HLH?
    A balanced diet rich in protein, antioxidants, and hydration supports recovery but cannot replace medical therapy.

13. What follow‑up is required?
    Regular monitoring of blood counts, liver function, and ferritin levels post‑treatment.

14. Can HLH relapse?
    Yes—especially in secondary HLH if triggers reoccur; early detection is critical.

15. Where can I find support?
    Histiocyte Society, patient advocacy groups, and specialized HLH treatment centers provide resources.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 27, 2025.